Q4/20 adj. EBITDA of USD 78.0m (+14% vs ARCe, +10% vs Cons.)
TCE guidance indicating 10% downside to Cons. Q1 EBITDA
Hygo transaction progressing according to plan with closing expected in H1
Overall, we view the report as stronger than expected
Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Q4/20 adj. EBITDA of USD 78.0m (+14% vs ARCe, +10% vs Cons.)
TCE guidance indicating 10% downside to Cons. Q1 EBITDA
Hygo transaction progressing according to plan with closing expected in H1
Overall, we view the report as stronger than expected
